The estimated Net Worth of David Gionco is at least 4.42 百万$ dollars as of 1 April 2020. David Gionco owns over 11,524 units of Stemline Therapeutics stock worth over 3,346,447$ and over the last 10 years David sold STML stock worth over 1,078,422$.
David has made over 18 trades of the Stemline Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently David sold 11,524 units of STML stock worth 55,200$ on 1 April 2020.
The largest trade David's ever made was selling 14,022 units of Stemline Therapeutics stock on 11 March 2019 worth over 155,784$. On average, David trades about 4,342 units every 76 days since 2015. As of 1 April 2020 David still owns at least 282,878 units of Stemline Therapeutics stock.
You can see the complete history of David Gionco stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, ELEVENTH FLOOR, NEW YORK, NY, 10022.
Over the last 12 years, insiders at Stemline Therapeutics have traded over 12,490,046$ worth of Stemline Therapeutics stock and bought 10,500 units worth 128,270$ . The most active insiders traders include Eric Dobmeier、Kenneth Hoberman、Ivan Bergstein. On average, Stemline Therapeutics executives and independent directors trade stock every 29 days with the average trade being worth of 169,110$. The most recent stock trade was executed by Robert Francomano on 4 May 2020, trading 272 units of STML stock currently worth 3,131$.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Stemline Therapeutics executives and other stock owners filed with the SEC include: